



19.02.2024

Impulze Data Protection and Pharmacovigilance Statement for Market Research Projects

Privacy and confidentiality

The protection of personal data and the preservation of confidentiality when processing the survey results are important concerns for us. We are therefore pleased to inform you as follows:

This survey as part of our market research efforts collects, among other things, information that falls under "personal data" according to data protection laws and is therefore protected.

In addition to your full name, we collect further information such as your opinion on certain therapies or which therapies you use in which situations. We also collect qualitative and quantitative data on your current focus of activity for our own participant statistics and to improve the relevance of our project inquiries to you.

We store this data and information with appropriate technical and organizational measures for a maximum period of 5 years in order to track changes longitudinally over several survey waves in aggregated form.

You can revoke your consent to data processing at any time with effect for the future (by e-mail to dataprotection@impulze.ch).

We respect your trust and protect your privacy. We will therefore never disclose the collected personal data to third parties or sell it on to third parties. Only aggregated data and information that does not allow any conclusions to be drawn about individual participants will be communicated to the clients of the survey.

Please also take note of our Privacy Policy. The privacy policy can be found here: <http://www.impulze.ch/data-protection.html>.

Pharmacovigilance notification

Events relevant to the safety of medicinal products or medical devices that are mentioned in the course of a market research survey must be passed on to our clients in accordance with the Therapeutic Products Act.

The survey may contain questions about adverse events, off-label use, product complaints or other safety-related information. If you mention an adverse event, an off-label use, a product complaint or other safety-relevant information in the survey, we will report this to the responsible office, even if the event has already been reported directly by you.

For cases of greater complexity, it may be necessary for us to ask you again specifically whether the client's pharmacovigilance department may contact you for further information. Only if you agree to this will we forward your name and e-mail address to the client's pharmacovigilance department. Otherwise, we will continue to report the matter without your contact details.



Contact at impulze GmbH and confirmation

If you have any questions, please contact the office responsible for data protection in our company at dataprotection@impulze.ch.

If you are taking part in an individual interview, you will be asked before the interview begins whether you have taken note of and agree to the information contained in this declaration.

To participate in an electronic survey, please click on the corresponding button.

Last change: 19.02.2024